Early escalation to tetracycline-class antibiotics and in-hospital outcomes in children with high-risk, early macrolide-unresponsive mycoplasma pneumoniae pneumonia: a target trial emulation

Background Macrolide resistance and poor early clinical response complicate the management of Mycoplasma pneumoniae pneumonia (MPP) in children. Clinical nonresponse does not necessarily indicate microbiologically confirmed resistance, and evidence regarding the timing and outcomes of tetracycline-class escalation in selected older children remains limited. Methods This single-center retrospective cohort study emulated a target trial using electronic medical records from January 2021 through December 2025. Hospitalized children aged 8–18 years with MPP were eligible if they had at least one temperature ≥38.0 °C during the 24 h preceding the 48-h time zero despite ongoing macrolide therapy and at least one prespecified high-risk disease-burden feature. Strategies were initiation of doxycycline or minocycline within the subsequent 24 h vs. continuation of non-tetracycline therapy. A clone–censor–weight approach with inverse probability of censoring weighting was used. The primary outcome was sustained defervescence, summarized by the 72-h probability and 7-day restricted mean time without defervescence. Results Among 684 eligible children, 191 received early tetracycline-class escalation, 479 continued non-tetracycline therapy, and 14 initiated fluoroquinolones. After weighting, all measured baseline covariates achieved adequate balance. The standardized probability of 72-h sustained defervescence was 74.8% with early escalation and 59.2% with continued non-tetracycline therapy (risk difference, 15.6%; 95% CI, 8.4%–22.8%; risk ratio, 1.26; 95% CI, 1.13–1.41). The 7-day restricted mean time without defervescence was 1.27 days shorter with early escalation (95% CI, 0.88–1.66 days shorter). Early escalation was also associated with lower risks of clinical deterioration and new radiological complications and with shorter hospitalization and antibiotic duration. Aminotransferase elevation was comparable, whereas gastrointestinal adverse events were more frequent. Findings were consistent across sensitivity analyses. Conclusions In hospitalized children aged 8–18 years with high-risk and early macrolide-unresponsive MPP, early doxycycline or minocycline escalation was associated with faster sustained defervescence and several favorable short-term hospital outcomes. These associations should not be interpreted as causal proof because of the retrospective single-center design, potential residual confounding, and absence of routine macrolide-resistance testing. Prospective multicenter studies are warranted before broader clinical application.

Authors

Publication Details

Journal
Frontiers in Pediatrics
Published
2026-11-18
DOI
https://doi.org/10.3389/fped.2026.1942992
Primary Topic
Pneumonia and Respiratory Infections
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Early escalation to tetracycline-class antibiotics and in-hospital outcomes in children with high-risk, early macrolide-unresponsive mycoplasma pneumoniae pneumonia: a target trial emulation

Li Yanwei, Junfeng Liu, Xiao Shi, Yinan Shen et al.
3 links
Frontiers in Pediatrics
Pneumonia and Respiratory Infections
article

Early escalation to tetracycline-class antibiotics and in-hospital outcomes in children with high-risk, early macrolide-unresponsive mycoplasma pneumoniae pneumonia: a target trial emulation

Li Yanwei, Junfeng Liu, Xiao Shi, Yinan Shen, Yueqian Li, Xuan Li
article en

Abstract

Background Macrolide resistance and poor early clinical response complicate the management of Mycoplasma pneumoniae pneumonia (MPP) in children. Clinical nonresponse does not necessarily indicate microbiologically confirmed resistance, and evidence regarding the timing and outcomes of tetracycline-class escalation in selected older children remains limited. Methods This single-center retrospective cohort study emulated a target trial using electronic medical records from January 2021 through December 2025. Hospitalized children aged 8–18 years with MPP were eligible if they had at least one temperature ≥38.0 °C during the 24 h preceding the 48-h time zero despite ongoing macrolide therapy and at least one prespecified high-risk disease-burden feature. Strategies were initiation of doxycycline or minocycline within the subsequent 24 h vs. continuation of non-tetracycline therapy. A clone–censor–weight approach with inverse probability of censoring weighting was used. The primary outcome was sustained defervescence, summarized by the 72-h probability and 7-day restricted mean time without defervescence. Results Among 684 eligible children, 191 received early tetracycline-class escalation, 479 continued non-tetracycline therapy, and 14 initiated fluoroquinolones. After weighting, all measured baseline covariates achieved adequate balance. The standardized probability of 72-h sustained defervescence was 74.8% with early escalation and 59.2% with continued non-tetracycline therapy (risk difference, 15.6%; 95% CI, 8.4%–22.8%; risk ratio, 1.26; 95% CI, 1.13–1.41). The 7-day restricted mean time without defervescence was 1.27 days shorter with early escalation (95% CI, 0.88–1.66 days shorter). Early escalation was also associated with lower risks of clinical deterioration and new radiological complications and with shorter hospitalization and antibiotic duration. Aminotransferase elevation was comparable, whereas gastrointestinal adverse events were more frequent. Findings were consistent across sensitivity analyses. Conclusions In hospitalized children aged 8–18 years with high-risk and early macrolide-unresponsive MPP, early doxycycline or minocycline escalation was associated with faster sustained defervescence and several favorable short-term hospital outcomes. These associations should not be interpreted as causal proof because of the retrospective single-center design, potential residual confounding, and absence of routine macrolide-resistance testing. Prospective multicenter studies are warranted before broader clinical application.

Frontiers in PediatricsVol. 14
Good health and well-being
Pneumonia and Respiratory Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon